ArticleAntimicrobial agents and chemotherapy2017
5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice.Nature communications · 2024Article
- Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition.Bioorganic & medicinal chemistry letters · 2023Article
- Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.Antimicrobial agents and chemotherapy · 2023Article
- An update onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- Comparative Characterization of CpCDPK1 and CpCDPK9, Two Potential Drug Targets Against Cryptosporidiosis.Microorganisms · 2022Article
- Spontaneous Selection ofAntimicrobial agents and chemotherapy · 2021Article
- Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis.ACS infectious diseases · 2021Article
- One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.Veterinary parasitology · 2021Review
- Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned.International journal for parasitology · 2020Review
- Characterization of Calcium-Dependent Protein Kinases 3, a Protein Involved in Growth ofFrontiers in microbiology · 2020Article
- Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.The Journal of infectious diseases · 2019Article
- Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.Journal of medicinal chemistry · 2019Article
- 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.ACS infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Wenlin HuangDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Ryan ChoiDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Matthew A HulversonDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Zhongsheng ZhangDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Molly C McCloskeyDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Deborah A SchaeferSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, USA.
Grant R WhitmanDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Lynn K BarrettDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Rama Subba Rao VidadalaDepartment of Chemistry, University of Washington, Seattle, Washington, USA.
Michael W RiggsSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, USA.
Dustin J MalyDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Wesley C Van VoorhisDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Kayode K OjoDivision of Allergy & Infectious Diseases, Center for Emerging & Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA ojo67kk@u.washington.edu erkang@u.washington.edu.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, Washington, USA ojo67kk@u.washington.edu erkang@u.washington.edu.
Funding
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4MCalcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0MDual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9MNIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NICHD NIH HHS R01 HD080670
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntiprotozoal AgentsCalcium-Calmodulin-Dependent Protein KinasesCryptosporidiosisCryptosporidium parvumMiceProtein Kinase InhibitorsProtein KinasesProtozoan ProteinsPyrazoles5-aminopyrazoleAntiprotozoal AgentsCalcium-Calmodulin-Dependent Protein KinasesProtein Kinase InhibitorsProtein KinasesProtozoan ProteinsPyrazoles5-aminopyrazole-4-carboxamidebumped kinase inhibitorsCryptosporidium parvum
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.